Skip to main content

Difficult-to-Treat Rheumatoid Arthritis

Dr. Arthur Kavanaugh | Abstract 1407 | ACR 2026
 

Transcription

Hi, it's Dr. Artie Kavanaugh from University of California, San Diego coming to you for RheumNow and I'm here at the ACR Convergence. First day of the meeting — really a packed meeting with a lot of great information already and a lot more to come.

Still a topic I'm going to talk about and we're talking about themes. We're talking about just principles of difficult-to-treat rheumatoid arthritis. And the reason I picked this topic — well, it's a hot topic and I think we've seen a lot more interest in this. We're talking about newer therapies, newer treatments, newer treatment algorithms for refractory arthritis. Some of them, if you think of the risk-benefit ratio, maybe they're a little bit riskier. So, would you want to have it for a population of patients where there's the greatest need? And as clinicians, I think we think maybe the greatest need is in the most refractory patients.

We've known forever in rheumatoid arthritis care that the more therapies you've tried, the more therapies you have failed, the more refractory you are, the less well you're going to do with the fifth therapy if you have been on four. And we've known that since the days of just conventional synthetic DMARDs. What about now? What do we know about this and the difficult-to-treat rheumatoid arthritis?

The EULAR group has come up with the definition of that which you can look up. It makes sense. It's a difficult concept I think for us clinicians. We all know the patients that we see in the clinic who are difficult to treat. We can identify them but it's hard to write that down. So what is this difficult to treat?

There's an abstract 1407 which looked at this with an interesting side take I believe, and that is we talk about difficult-to-treat RA. Well, how stable is that? What happens to people if you go to the clinic and you find a bunch of people who are classified difficult-to-treat RA using the EULAR criteria? What happens to them over time? So they looked at this in this abstract and what they found is relevant to people who are interested in coming up with treatment algorithms and therapeutic studies for difficult-to-treat RA.

What they found is about half the patients seemed to be stable in difficult-to-treat RA — meaning they were difficult-to-treat RA at subsequent time points. The other half were less stable. Some dropped right out — they were no longer in difficult-to-treat anymore. Some came in and out to various degrees. So interesting question: if you were planning to treat difficult-to-treat RA patients, who would you pick? I think the first blush you might say, well, the ones who are in difficult-to-treat all the time because they're the toughest, they're the most refractory — but maybe they're the ones more likely to be influenced by things like pain and they may never respond to immunomodulatory therapies. But if you have those who come in and out, and the investigators looked at this, treatment didn't necessarily relate to them coming in and out of difficult-to-treat.

So fascinating question. It's one of those things that we all know what difficult-to-treat means when we go to the clinic, but how do you translate that into something where you can write it down and put it into a clinical trial? Dr. Artie Kavanaugh coming to you from ACR Convergence 2026 for RheumNow.

ADD THE FIRST COMMENT

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

×